收藏切换
Analysis on classification review procedure and communication work of advanced therapy medicinal products by the European Medicines Agency
收藏切换
Fan ZHANG, Yu-tao WANG, Yun-rui DI, Jun WANG
Chinese Journal of Clinical Pharmacology | 2026, 42(11) : 1624 - 1630
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2026, 42(11): 1624-1630
• Drug Evaluation and Administration •
Analysis on classification review procedure and communication work of advanced therapy medicinal products by the European Medicines Agency
Full
Fan ZHANG, Yu-tao WANG, Yun-rui DI, Jun WANG
Affiliations
  • Center for Drug Evaluation, National Medical Products Administration, Beijing 100076, China
Published: 2026-06-17 doi: 10.13699/j.cnki.1001-6821.2026.11.020
Outline
收藏切换

Advanced therapy medicinal products (ATMPs), as a cutting-edge frontier in the current biomedical sector, hold enormous potential to address unmet clinical medical needs. Nevertheless, such products are confronted with multiple challenges including high technical complexity, distinctive research and development risks and substantial investment costs. Their accurate classification and scientific regulation are critical to advancing the standardized development of the industry. Over years of practical experience, the European Medicines Agency (EMA) has established a robust legal and regulatory system, accompanied by a series of issued guidelines, thus forming a relatively mature regulatory framework. Furthermore, relying on the Committee for Advanced Therapies (CAT), the EMA has developed a comprehensive mechanism for the classification, designation, and communication of ATMPs, which serves as an important reference for the global regulation of ATMPs. This paper systematically elaborates on the classification criteria and designation procedures of ATMPs formulated by the EMA, and introduces its practical communication practices, including scientific advice and innovation task force briefings. This paper provides insights and references for improving China’s ATMP classification management system, optimizing the evaluation and communication mechanism, and constructing a scientific and efficient regulatory framework.

advanced therapy medicinal products  /  advanced therapy medicinal products  /  European Medicines Agency  /  classification  /  communication  /  laws and regulations
张帆, 王宇涛, 邸云瑞, 王骏. 欧洲药品管理局先进治疗药物分类认定及沟通交流工作情况分析. 中国临床药理学杂志, 2026 , 42 (11) : 1624 -1630 . DOI: 10.13699/j.cnki.1001-6821.2026.11.020
Fan ZHANG, Yu-tao WANG, Yun-rui DI, Jun WANG. Analysis on classification review procedure and communication work of advanced therapy medicinal products by the European Medicines Agency[J]. Chinese Journal of Clinical Pharmacology, 2026 , 42 (11) : 1624 -1630 . DOI: 10.13699/j.cnki.1001-6821.2026.11.020
Year 2026 volume 42 Issue 11
328
59
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2026.11.020
  • Receive Date:2026-04-01
  • Online Date:2026-08-06
  • Published:2026-06-17
Article Data
Affiliations
History
  • Received:2026-04-01
Affiliations
    Center for Drug Evaluation, National Medical Products Administration, Beijing 100076, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2026.11.020
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT